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Background: Attention-deficit hyperactivity disorder (ADHD) is a complex disorder in
terms of etiology, clinical presentation, and treatment outcome. Pharmacological and psy-
chological interventions are recommended as primary treatments in ADHD; however, other
nonpharmacological intervention such as a dietary supplementation with omega-3 polyunsa-
turated fatty acids (ω-3 PUFAs) has emerged as an attractive option.
Purpose: The objective of the present study was to assess whether dietary supplementation
with highly concentrated ω-3 docosahexaenoic acid (DHA) triglyceride may improve symp-
toms in ADHD.
Method: A 6-month prospective double-blind placebo-controlled randomized clinical trial
was designed in 66 patients with ADHD, aged between 6 and 18 years. Participants in the
experimental group received a combination of ω-3 fatty acids (DHA 1,000 mg, eicosapen-
taenoic acid 90 mg, and docosapentaenoic acid 150 mg). Instruments included d2-test,
AULA Nesplora, EDAH scales, and abbreviated Conner’s Rating Scale.
Results: In the cognitive test, between-group differences were not found, but within-group
differences were of a greater magnitude in the DHA group. Between-group differences in
favor of the DHA arm were observed in behavioral measures, which were already detected
after 3 months of treatment. Results were not changed when adjusted by ADHD medication.
Conclusions: This study provides further evidence of the beneficial effect of supplementa-
tion with ω-3 DHA in the management of ADHD.
Keywords: omega 3, PUFAs, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA),
attention-deficit hyperactivity disorder (ADHD)
Introduction
Attention-deficit hyperactivity disorder (ADHD) is a complex disorder in terms of
etiology, clinical presentation, and treatment outcome.1,2 Pharmacological and
psychological interventions are generally recommended as primary treatments in
youths with ADHD,3 but other nonpharmacological strategies have been the subject
of growing interest for their potential role as alternative or additive approaches.4–6
Dietary supplementation with omega-3 polyunsaturated fatty acids (ω-3 PUFAs)
has emerged as an attractive nonpharmacological option. The rationale for the use
of ω-3 PUFAs in ADHD is based on mechanisms supporting the importance of
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essential fatty acids in neural tissue and evidence from
studies showing that ω-3 PUFAs may be relevant to
ADHD.7
The ω-3 PUFAs, eicosapentaenoic acid (EPA) and
especially docosahexaenoic acid (DHA), play a key role
in brain development and function,8,9 but only a small
amount is synthesized by the human body. A continued
dietary supply of ω-3 fatty acids is needed due to limited
storage of these compounds in adipose tissue. The pleio-
tropic effects of DHA appear to influence many different
signaling pathways, receptor systems, enzyme activities,
synaptic plasticity, and membrane structure that ultimately
lead to better brain functioning.10,11 Experimental deple-
tion of brain DHA in animal studies is associated with
reduction of both dopaminergic and serotonergic
neurotransmission12 and behavioral impairments.13 Also,
low brain DHA content has been shown in some neurode-
generative and neuropsychiatric disorders.14,15
In relation to ADHD, lower levels of PUFAs in blood
and red blood cells and higher ω-6/ω-3 ratios have been
associated with the severity of ADHD,16–19 and increased
DHA and EPA concentrations in erythrocyte membranes
resulting from ω-3 PUFAs supplementation appeared to
ameliorate symptoms of ADHD.20 Systematic reviews and
meta-analyses of randomized controlled trials (RCTs)
assessing outcomes of supplementation with PUFAs have
shown inconsistent results,16,18,21–27 possibly due to het-
erogeneity of clinical samples, inclusion of patients with
diagnosis other than ADHD, non-parallel designs, or
mixed supplementation interventions. However, a recent
meta-analysis of seven RCTs with 534 youths with ADHD
reported by Chang et al7 showed that ω-3 PUFA supple-
mentation significantly improved parental reports of total
symptom score, inattention, and hyperactivity. In two spe-
cific measurements, the Conner’s cognition and the
Conner’s DSM-IV inattention subscales, ω-3 PUFAs had
also a significant effect on both scores.7 Moreover, in three
RCTs, ω-3 PUFA supplementation improved cognitive
measures associated with attention.7 The findings of this
meta-analysis provide further support to the rationale for
using ω-3 PUFAs as a treatment option for ADHD.
Interestingly, ω-3 supplements used in previous studies
of ADHD were low-dose EPA and DHA combinations,
despite being recognized that DHA is a physiologically
essential nutrient in the brain where it is required in high
concentrations for providing optimal neuronal
functioning.28,29 In direct contrast to DHA, EPA is found
in near trace amounts in the brain and has a minor
contribution to brain functioning.30 Our objective was,
therefore, to investigate the effect of dietary supplementa-
tion with highly concentrated DHA triglyceride on ADHD




The study was a randomized double-blind placebo-con-
trolled parallel trial involving parallel treatment for 6
months. The study was approved by the Ethics
Committee of the Principality of Asturias (reference:
CPMP/ICH/135/95, code: TDAH-Oviedo) and took into
account the ethical principles for medical research invol-
ving human subjects as stated in the Declaration of
Helsinki. Written informed consent was obtained from
the parents of all subjects as well as from participants
aged 12 years and older. Participants had volunteered to
be involved in this study, and they were not given any
incentive to take part in it. Once written consent was
obtained, the corresponding tests were conducted to verify
the diagnosis and to participate in this research. The study
was registered in the European Clinical Trials Database
(EudraCT trial number 2017–000866-31 for the Sponsor’s
Protocol code number TDAH-OVIEDO).
Participants
Boys and girls between 6 and 18 years of age with a DSM-
5 diagnosis of ADHD (DSM-5 American Psychiatric
Association, 2013) were recruited through the Faculty of
Psychology at the University of Oviedo. The clinical diag-
nosis was confirmed by a trained researcher using the
Diagnostic Interview Schedule for Children–Parent
Version (DISC-P). Patients with any subtype of ADHD
(hyperactive-impulsive, inattentive, combined hyperac-
tive-inattentive) were eligible. The children with ADHD
were either medication naïve or using psychostimulant
medication. Exclusion criteria were blood coagulation dis-
orders, cognitive impairment or autism spectrum disorder,
known intolerance to fish proteins, and treatment with
dietary supplements containing ω-6 or ω-3 PUFAs during
the month preceding inclusion. Participants with extreme
total IQ scores lower than 70 and greater than 130 using
the Wechsler Intelligence Scales for Children, fourth edi-
tion (WISC-IV)31 were excluded. Study eligibility and
pre- and postintervention ratings of study procedures
were assessed by psychologists.
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Randomization and blinding
Randomization (1:1) was performed according to a com-
puter-generated random sequence, which was used to allo-
cate the participants either to the dietary supplement or the
placebo group. Participants, parents, and investigators
assessing outcome measures were blind to the intervention
condition. Blinding was maintained until data analysis was
completed.
Intervention
The DHA studied supplement consisted of a banana-fla-
vored emulsion (4.7 g, 5 mL sachets) (Brudy NEN
Emulsión; Brudy Lab, S.L., Barcelona, Spain), registered
as a “food for special medical purposes” at the Spanish
Agency of Consumption, Food Security, and Nutrition
(AECOSAN), and requiring medical prescription and
supervision of treatment. This supplement has a high-con-
tent DHA triglyceride having a high antioxidant activity
patented to prevent cellular oxidative damage.32,33 Each
sachet provided a combination of ω-3 fatty acids (DHA
1,000 mg, EPA 90 mg, and docosapentaenoic acid 150
mg), vitamin E (D-alpha-tocopherol) 4.5 mg as an antiox-
idant, and carbohydrates 0.94 g (fructose 0.46 g). Doses
were 1 sachet/day in children weighing ≤32 kg and 2
sachets/day in those weighing >32 kg. The placebo sachets
had the same composition and were indistinguishable from
the active product. They were composed of the same
amount of olive oil with banana flavor to give a similar
taste and smell. Treatment duration was 6 months. The use
of the current psychostimulant medication was allowed,
but other psychotropic medications were not.
Assessments
Prespecified outcome measures were changes observed in
the study instruments (cognitive and
behavioral variables) after 6 months of treatment in the
DHA and placebo groups as compared with baseline in the
between-group and within-group comparisons.
The study included a pre-treatment visit (time 0, base-
line), an intermediate visit at 3 months of starting dietary
supplementation (time 1), and a post-treatment visit at the
end of the study (time 2, 6 months). At baseline, partici-
pants completed the d2 test of attention and the AULA
Nesplora (virtual) test, whereas parents completed the
Scale for the Assessment of Attention Deficit
Hyperactivity Disorder (EDAH) (as per: EDAH version
for families) and the Conner’s Parents Rating Scale. At the
intermediate visit, parents completed the EDAH and the
Conner’s questionnaires. The same instruments used at
baseline were administered to patients and families at the
final visit at 6 months.
The investigational product was delivered to the patient at
baseline for 90-day treatment and at an intermediate visit at 3
months for a further 90-day treatment. At each visit, partici-
pants and their families were carefully interviewed regarding
adherence and appearance of adverse events. Compliance
with DHA supplementation was assessed by return of sup-
plementation sachet counts and analytical data especially
erythrocyte membrane DHA content.
The d2 test measures the ability to concentrate and sustain
attention. It was originally described by Brickenkamp and
Zillmer34 and a Spanish validated version was used in our
study.35 This paper and pencil test asks to cross any letter “d”
with two marks (above or below, in any order). The distrac-
tors are a “p” with two marks or a “d” with one or three
marks. It is made up of 14 lines with 47 characters each for a
total of 658 items, and the subject is given 20 s for each line.
The results scores are: TR, overall answers, number of ele-
ments tried on the 14 lines; TA, number of correct guesses,
that is, number of correct relevant elements; O, omitted
elements, number of relevant elements tried but not marked;
C, commissions, number of irrelevant elements marked;
TOT, total test effectiveness, that is TR – (O+C); CON,
concentration index, TA-C; and VAR, variation index or
difference (TR+)-(TR-), where TR+ is the line with the
greater number of tried elements, and TR- is the line with a
lower number of elements tried. Higher scores of TA, TOT,
and CON indicate better performance, and higher scores of
O, C, and VAR indicate worse performance.
The AULA Nesplora test36–38 measures attention,
impulsivity, processing speed, and motor activity in a
virtual reality environment, which is shown through 3D
glasses equipped with motion sensors and headphones.
The participant takes the perspective of a student sitting
in one of the desks of a classroom and facing the black-
board. The virtual environment and the earphones present
a series of visual and auditory stimuli to which the user
must respond. AULA comprises two main tasks: a “no-x”
(“no-go” paradigm) task in which the participant must
press the button whenever the presented stimulus is differ-
ent from the target stimulus (whenever he/she does not see
or hear “apple”) and an “x” (“go” paradigm) task, in which
the participant must press the button whenever he/she sees
or hears the target stimulus, more specifically when he/she
sees or hears “seven”. Both visual and auditory stimuli are
Dovepress Rodríguez et al
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presented and, simultaneously, ecological distractors
appear progressively, similar to those that may be found
in a real-life school classroom (eg, teacher’s walk, paper
ball, bell rings, a child passes a note to another student, the
teacher’s pen drops, ambulance passes across the street,
etc.). The test is completed in about 20 mins and measures
the following variables: omissions (O), errors when the
participant should respond to a target stimulus but does not
do so; commissions (C), errors when the participant clicks
the button even if the target stimulus has not been pre-
sented; and average response time for correct responses
(RT), reaction time in milliseconds. A high number of
omissions is related to attention-deficit symptoms, a high
number of commissions indicates impulsivity, and TR is a
measure of processing speed (the longer response time, the
greater the attention deficit [AD]). Measures are differen-
tiated by sensory modality (visual vs auditory), presence/
absence of distractors, and task type (“no-go” vs “go”).
The EDAH version for families39 is composed of 20
items assessing the frequency that children and adolescents
show behaviors related to AD and/or hyperactivity/impulsiv-
ity, rating from 0 (not at all present) to 4 (very much present).
This scale provides indicators about ADHD and helps to
verify and distinguish between the three ADHD subtypes.
It is based on the symptomatology for ADHA listed in the
DSM-5 manual. The abbreviated Conners‘ Rating Scale for
parents (10-item)40 is a valid instrument assessing only the
attention component and is usually used as a screening
instrument for the identification of ADHD.
Biochemical analysis
The content of ω-3 DHA in the erythrocyte was measured at
baseline and at the end of the study in those participants who
gave consent for peripheral blood sampling. The composition
of FAs was determined using the method described by
Lepage and Roy41 analyzed by gas chromatography–mass
spectrometry and identified by comparing the elution pattern
and relative retention times of FA methyl esters with a
reference FA methyl ester mixture (GLC-44 Nu-Check
Prep. Inc, Elysian, MN, USA). The results were expressed
in relative amounts (percentage of total FA).
Statistical analysis
Descriptive statistics for the dependent variables were
analyzed in each group, paying special attention to kurto-
sis and skewness values. Kline’s criterion42 was used,
according to which the maximum scores accepted for
skewness and kurtosis range between 3 and 10. The
study variables met this criterion, which allowed perform-
ing parametric analyses. Categorical variables are
expressed as frequencies and percentages and continuous
variables as mean and standard deviation (SD). To inves-
tigate treatment effects, all study variables (d2, AULA
Nesplora, EDAH for families, and Conners‘ Rating Scale
for parents) were fed into analysis of covariance
(ANCOVA) models, with medication as a blocking factor.
Repeated-measures ANOVA analyses were used to assess
within-group differences. Further analyses included
differences related to sex as a blocking factor and the
interaction sex ⨰ treatment response, differences related to
medication as a blocking factor and the interaction medi-
cation ⨰ treatment response, and the interaction time ⨰
treatment. The magnitude of the effect was expressed in
Cohen’s d according to which the effect is small when
ηp2=0.01 (d=0.20), medium when ηp2=0.059 (d=0.50),
and high when ηp2=0.138 (d =0.80). Analyses were per-
formed in the per-protocol (PP) population, that is, all
randomized patients who completed the 6-month study
period, and in the intention-to-treat population (ITT) of
all randomized patients. Statistical significance was set at
P<0.05. The SPSS statistical package 24.0 (SPSS,
Chicago, IL, USA) was used for the analysis of data.
Results
Between February 1 and March 31, 2017, 98 participants
diagnosed with ADHD were screened for eligibility, 95 of
which met the inclusion criteria and were randomized, 49
to the DHA group and 46 to placebo. There were 67 boys
and 28 girls, aged between 6 and 19 years. The mean IQ
score was 100.1 (15.1). Results obtained in the 95 rando-
mized patients (ITT population) are described in the
Supplementary material.
A total of 66 participants (69.5%) completed the study
(DHA, n=32, placebo, n=34) and underwent the final eva-
luation assessment between September 1 and October 31,
2017. The flowchart of participants is shown in Figure 1.
Main reasons for not completing the study were refusal to
continue and lost to follow-up (change of residence). All
participants were Caucasian. There were 47 boys and 19
girls, with a mean age of 11.7 (3.1) years and a mean IQ
score of 100.3 (15.5). Twenty-four (75% patients in the
DHA group) and 24 (70.6%) in the placebo group received
pharmacological medication, mostly stimulants followed
by atomoxetine. Also, comorbid conditions were present
in 12 and 4 patients in the DHA and placebo groups,
respectively, including dyslexia, Tourette’s syndrome,
Rodríguez et al Dovepress
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reading difficulties, anxiety, dyscalculia, and psychomotor
and behavioral problems. Results here presented were
obtained in the PP data set of 66 participants.
Cognitive variables
At baseline, there were no significant differences between
the two study groups regarding variables of the d2 and
AULA Nesplora tests (Tables 1 and 2).
In both study groups, within-group differences in the
d2 test were statistically significant regarding improve-
ments in total test effectiveness (TOT), overall answers
(TR), correct relevant elements marked (TA), and concen-
tration index (CON), as well as significant decreases in
commissions (C) (Table 1). The interaction time ⨰ group
was not statistically significant in any case. Between-group
differences in any variables of the d2 test were not found,
but the magnitudes of within-group differences were
DHA group 
N=32 
Refuse to continue 
N=14
Placebo group  
N=34 






















Time 0 (baseline) 
DHA group 
N=46 
Placebo group  
N=49 










































Figure 1 Participants flow from enrollment to final sample.
Abbreviations: DHA, decosahexaenoic acid; IQ, intellectual quotient; WISC, Wechsler Intelligence Scale for Children; ADHD, attention-deficit hyperactivity disorder;
EDAH, Assessment of Attention Deficit Hyperactivity Disorder Scale.
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greater in the DHA group than in the placebo group
(Figure 2), with higher effect sizes in the experimental
group. In the ANCOVA models adjusted by presence or
absence of ADHD medication, pharmacological treatment
had no effect on d2 variables. Similar results were
obtained in the analysis of the ITT data set (see Table S1).
In the AULA Nesplora test, within-group comparisons
showed statistically significant improvements in omissions
and response time in the visual modality in the DHA group
and response time in the visual sensory modality and in the
absence of distractors condition in the placebo group
(Table 2). The magnitude of mean changes for omissions
in the visual sensory modality was 6.4 in the DHA group
and 4.5 in the placebo group, showing a higher effect size
in the first group. Also, the mean change in the response
time at the end of the study as compared with baseline was
134.0 in the DHA group and 107.5 in the placebo arm.
Between-group differences in results of the AULA tests
were not observed. ADHD medication as a covariable had
no effect on the results obtained. The interaction time ⨰
group was not statistically significant in any of the studied
variables. Results obtained in the analysis of the PP data
set were replicated in the ITT population (see Table S2).
Behavioral variables
At baseline, statistically significant differences between
the study groups in components of the EDAH scale and
the Conner’s scale were not found, except for the AD of
the EDAH with higher impairment in the intervention
group than in the placebo group (Table 3).
Results of EDAH scale for families and Conner`s
Rating Scale for parents are shown in Table 3. In the
DHA group, within-group significant differences at fol-
low-up assessments as compared with baseline were
observed in AD and attention-deficit hyperactivity
(ADHD) components of the EDAH scale, with reduction
of symptoms already noted after 3 months of treatment. By
contrast, within-group differences were not found in the
placebo group in any variables, although the increase in
the means indicated deterioration in all the group of symp-
toms over time. Between-group differences at the end of
treatment were observed for all three components of the
EDAH scale. In the Conner’s scale, within-group differ-
ences were found in both study groups. The DHA group
showed a decrease in the symptoms of ADHD from the
first to the third moment, while the placebo group showed
an increase over time. Between-group differences were not
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statistically significant only in the case of AD and ADHD
variables from the EDAH scale (see Table 3). As shown in
Table S3 of the Supplementary material, similar results
were found in the analysis of the ITT population.
Finally, when differences related to sex as a blocking
factor or the interaction sex ⨰ treatment response as well
as differences related medication as a blocking factor or
the interaction medication ⨰ treatment response were ana-
lyzed, no statistically significant differences in baseline or
postintervention variables (d2, AULA Nesplora, EDAH,
and Conner`s) between the two study groups were found
(data not shown), with the exception of the variable
ADHD from EDAH in the post-test, where the medication
groups scored statistically higher than the n onmedication
groups, in both the treatment and the placebo conditions.
Adherence and safety
A total of 23 participants (34.8%) (DHA group, n=12;
placebo group, n=11) gave consent for blood sampling.
At baseline, DHA content of the erythrocyte membrane
expressed as % of total FA was 3.4 (0.4) and 3.6 (0.4) in
the DHA and placebo groups, respectively. At the end of
treatment, however, DHA content of the erythrocyte mem-
brane increased significantly in the DHA group as com-
pared with placebo (5.7 [0.7] vs 3.7 [0.6]; P<0.001). These
results confirm DHA treatment adherence and differences
between the placebo and DHA groups. None of the parti-
cipants was excluded due to lack of adherence.
Over the course of the 6 months, no instances of either
major or minor adverse events were reported.
Discussion
This study investigated the effects of 6-month supplemen-
tation with highly concentrated DHA in the triglyceride
form on cognitive and behavioral performance in children
and adolescents diagnosed with ADHD. An increased
erythrocyte membrane DHA is a reliable indirect indicator
of good adherence in the supplemented group with the
active product. The ω-3 PUFA DHA is found in large
amounts in the phospholipids of neuronal membranes
and has been shown to be relevant in brain function due
to its involvement in many aspects, including membrane
fluidity and interactions with key regulatory proteins, cell
growth, gene expression, neural signaling, modulating the
synthesis, transport and release of neurotransmitters,
endothelial function, and neuronal survival.29,43–45 On
the other hand, EPA is not a significant structural compo-
nent of brain tissue, and DHA is several hundred-fold
more abundant than EPA in the brain.30 The key role of
DHA to contribute to optimal conditions for brain
functioning46 was the rationale for using a highly concen-
trated DHA in the form of triglyceride as the investiga-
tional product. In this respect, this study is the first to
investigate the effects of highly concentrated DHA sup-















































Figure 2 Mean differences between the final visit at 6 months and baseline in d2 variables with statistically significance in within-group comparisons.
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In relation to the effect of DHA supplementation on
cognitive variables, d2, and AULA Nesplora executive func-
tion tests, differences between participants supplemented
with DHA or placebo were not found. In fact, considerable
improvement in attention variables during the 6 months of
treatment occurred in both study groups. However, this study
population was a clinical sample of ADHD belonging to
different associations and clinics of our Principality of
Asturias community, which means that all participants were
receiving psychopedagogical and/or specific clinical inter-
ventions during the duration of the study. Although between-
group differences were not observed, within-group improve-
ments of almost all variables of the d2 test (selective atten-
tion) and variables related to visual attention (sustain
attention tasks) in the AULA Nesplora test were of higher
magnitude in the DHA supplementation group. The charac-
teristics of the study sample (receiving clinical and/or psy-
chopedagogical interventions) may explain that cognitive-
attention changes may take longer to appear than improve-
ments noted in behavioral features of ADHD. Of note, the
greater magnitude of improvement in cognitive domains
observed in the DHA-supplemented group opens an encoura-
ging perspective for further studies in larger samples of
youths with ADHD.
DHA supplementation for 6 months had a beneficial
effect on symptoms of ADHD as shown by scores of the
EDAH questionnaire for families. In this case, relevant
between-group differences were found, with improve-
ments in ADHD symptoms already evident after 3 months
of treatment. Differences in the Conner’s scale were not
observed, although there was a trend for improvement in
the DHA-supplemented group. The characteristics of the
10-item abbreviated instrument joining hyperactivity/
impulsivity and AD symptoms may account for the results
obtained, since this instrument is less specific than the
EDAH scale in the discrimination of ADHD symptoms.
Findings of the present study pointing toward a beneficial
effect of DHA supplementation in the management of
ADHD are in line with previous research.7,47,48 In a recent
meta-analysis by Chang et al7 of seven RCTs totalling 534
youth with ADHD, the authors concluded that PUFA supple-
mentation can improve both clinical symptoms and cognitive
performance in children and adolescents with ADHD,
although the number of studies showing significant changes
at a behavioral level – clinical symptoms – is greater than
those reporting cognitive changes. The authors also con-
cluded that there is an important deficiency in ω-3 PUFAs
levels in these populations. In the same line, Bos et al47
examined the effects of dietary ω-3 supplementation on
ADHD behavior and cognitive variables in a sample of 40
boys ADHD and 39 controls, aged 8–14 years, included in a
4-month double-blind randomized placebo-controlled trial.
The authors found an improvement in attentional symptoms
rated by parents, in both study groups. However, changes at a
cognitive level, including cognitive control tasks and fMRI
measures of brain activity, were not observed. In the present
study, covering a 6-month time period, some changes in
cognitive variables were found at intrasubject level with
generally greater improvements in the DHA group.
Interestingly, in a recent 6-month randomized placebo-con-
trolled study in 50 participants aged 7 to 14 years with
ADHD, DHA supplementation showed a significant, none-
theless quite small, effect of psychosocial functioning, emo-
tional problems, and focused attention, but failed to be
superior as compared to placebo in parent ratings of ADHD
behaviors.48 In this study, however, participants assigned to
the experimental group received a dose of 500 mg algal
DHA, which is half the DHA dose used in our study. The
authors concluded that in the light of the absence of adverse
events and somewhat positive effects of cognitive difficul-
ties, DHA supplementation could be reasonably followed-up
in future intervention studies.48 A recent study based on a
Spanish population-based birth cohort provided interesting
data on the potential modulating effect of material diet during
pregnancy on the risk of developing long-termADHD symp-
toms in the offspring.49 In this observational study, the
authors measured the ratio of arachidonic acid (ω-6) and
DHA and EPA (ω-3) concentrations in 953 cord blood sam-
ples and followed 642 children up to 7 years of age. Themain
finding was that a higher ω-6:ω-3 ratio in cord blood was
associated with a higher ADHD index at 7 years using the 27-
item Revised Conners’ Parent Rating Scale Short Form, with
an increase in ADHD symptom scores about 13% per each
ω-6:-3 ratio unit. On the whole, our findings together with
previous research would provide support to the rationale for
using ω-3 PUFAs as a treatment option for ADHD symp-
toms, and potentially for their cognitive correlates.
The present study should be interpreted considering
some limitations, particularly the small sample size,
thereby decreasing our ability to detect between-group
differences in cognitive variables, and the fact that recruit-
ment was based on a convenience (availability) sample.
Although analyses were adjusted by ADHD medication,
the effect or the intensity of concurrent psychological
interventions was not evaluated, nor whether age range
had any effect on outcome. On the other hand, doses of
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the pharmacological medication (stimulants, atomoxetine),
intensity of psychological treatment, or eventual intensity
of physical activity that could interfere with the results
were not registered. A separate analysis for naïve patients
and patients taken ADHD medications was not performed
because a large majority (more than 70%) of participants
was under pharmacological treatment. Cardiovascular data
were not evaluated, so that a potential effect of dietary ω-3
supplementation improving cardiovascular risk in stimu-
lant-treated patients was not explored. Biochemical ana-
lyses were performed in a relatively small percentage of
participants, which prevented a more complete assessment
of FA profile as well as to establish a correlation between
biochemical and clinical findings. Although compliance
with the nutraceutical formulation was checked at study
visits by asking the participants to bring the empty boxes,
and the investigator insisted on the importance of an
adequate daily dosing, the lack of control over dietary
intake of the subjects was among the limitations of the
study. The fact that all participants had unequivocal diag-
nosis of ADHD and the randomized double-blind placebo-
controlled design are strengths of the study.
Also, the use of the AULA Nesplora is a distinctive
methodological feature since this new tool based on virtual
reality has not been used in previous RCTs of ω-3 PUFAs
supplementation for ADHD. External validity of research
findings applies to a target population of Caucasian boys
and girls aged 6–18 years diagnosed with ADHD (any
type) given a highly concentrated dietary DHA supple-
ment similar to that used in the study. A target population
using other ω-3 PUFAs (composition/doses) will produce
biased inferences.
Conclusion
The present study adds to evidence suggesting that ω-3
DHA dietary supplementation may be a beneficial com-
plementary therapeutic approach in children and adoles-
cents with ADHD. Further research is warranted to
continue to explore the benefits of ω-3 DHA supplementa-
tion and the involvement of ω-3 PUFAs in the pathoge-
netic mechanism of ADHD.
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Supplementary materials
Table S1 Changes of variables of the d2 test at the end of the study as compared with baseline in the two study groups (within-group
comparisons). Analysis in the ITT sample
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9.28 (12.8) 8.34 (8.3) 0.724
(0.005)





4.61 (6.6) 1.18 (1.3) 0.010
(0.220)
3.09 (5.3) 1.15 (1.5) 0.036
(0.127)
0.322 0.016









Variability (VAR) 12.84 (4.8) 14.28 (5.4) 0.362
(0.035)
13.42 (5.4) 13.97 (5.3) 0.703
(0.005)
0.674 0.003
Note: There were within-group differences in both groups in all the variables, with the exception of omissions and variability. Both groups improved their performance in
the task. Effect sizes were high in all cases, but slightly higher in the case of the DHA group in some variables. Concerning differences between the groups, no statistically
significant differences were found neither at the beginning nor the end of the intervention. The effect of the pharmacological treatment was not statistically significant in any
case. The interaction time ⨰ treatment did not reach statistical significance.
Abbreviation: ITT, intention-to-treat; DHA, decosahexaenoic acid; SD, standard deviation; ES, effect size.
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Table S3 Changes of variables of the EDAH scale for families and Conner’s Rating Scale for parents at the end of the study as
compared with baseline in the two study groups (within-group comparisons). Analysis in the ITT sample
Instrument DHA group (n=46) Placebo group (n=49) Between-group P-value (P/ES)
EDAH version for families. mean (SD)
Hyperactivity (H)
Baseline 8.5 (3.1) 8.0 (3.2) 0.272 (0.016)
3 months 7.3 (3.1) 7.7 (3.0) 0.621 (0.005)
6 months 6.8 (3.2) 8.5 (3.3) 0.008 (0.124)
Within-group P-value (P-value/ES) <0.001 (0.455) 0.072 (183)
Interaction time x group (P-value/ES) 0.001 (0.242)
Attention deficit (AD)
Baseline 10.4 (2.6) 8.8 (2.8) 0.004 (0.108)
3 months 9.0 (3.0) 9.2 (3.0) 0.403 (0.013)
6 months 8.7 (2.9) 9.5 (2.5) 0.171 (0.033)
Within-group P-value (P-value/ES) 0.009 (0.339) 0.353 (0.072)
Interaction time x group (P-value/ES) 0.004 (0.190)
Attention deficit and hyperactivity (ADHD)
Baseline 18.8 (5.1) 16.7 (3.9) 0.007 (0.094)
3 months 16.4 (5.3) 17.1 (4.2) 0.854 (0.360)
6 months 15.5 (4.7) 18.3 (4.1) 0.017 (0.101)
Within-group P-value (P-value/ES) < 0.001 (0.522) 0.068 (0.187)
Interaction time x group (P-value/ES) <0.001 (0.310)
Conner’s Rating Scale for parents. mean (SD)
Baseline 25.6 (4.2) 25.0 (4.8) 0.151 (0.027)
3 months 23.0 (4.6) 23.7 (4.3) 0.656 (<0.001)
6 months 23.6 (4.1) 24.9 (5.2) 0.330 (0.020)
Within-group P-value (P-value/ES) 0.032 (0.319) 0.352 (0.088)
Interaction time x group (P-value/ES) 0.274 (0.063)
Note: There was a systematic and statistically significant reduction of ADHD in the DHA group, whereas in the placebo group, symptoms appear to be stable or even an
increase in mean values was found. The interaction time x treatment was statistically significant in all variables of the EDAH test. In relation to between-group differences,
once considering differences in the pre-test and medication an covariables, statistically significant differences in the post-test between the two groups were observed in
symptoms of hyperactivity and combined hyperactivity/attention deficit symptoms, in which mean values were higher in the placebo group. Pharmacological treatment did
not have a significant effect on this relationship, although differences in the pre-test had an effect in all cases.
Abbreviation: ES, effect size.
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